Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A1-3338 (B1801014)~Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~Exclusion criteria for subject planning to continue investigational product:~withdrawal from investigational product in study 0881A1-3338 for any reason (safety or non-safety).~History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma in situ.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).